SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

2/9/24 9:28:31 AM ET

Medical/Dental Instruments

Health Care

Get the next $NVCR alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.10 NOVOCURE LTD COMMON STOCK Cusip #G6674U108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G6674U108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 15,961,924 Item 6: 0 Item 7: 15,962,765 Item 8: 0 Item 9: 15,962,765 Item 11: 14.937% Item 12: HC Cusip #G6674U108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 15,962,765 Item 8: 0 Item 9: 15,962,765 Item 11: 14.937% Item 12: IN Item 1(a). Name of Issuer: NOVOCURE LTD Item 1(b). Address of Issuer's Principal Executive Offices: No. 4 The Forum, Grenville Street St. Helier, JE2 4UF Jersey Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: G6674U108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 15,962,765 (b) Percent of Class: 14.937% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 15,962,765 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NOVOCURE LTD. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of NOVOCURE LTD, amounted to 6,869,190 shares or 6.428% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of NOVOCURE LTD at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $NVCR alert in real time by email

Recent Analyst Ratings for

$NVCR

Date	Price Target	Rating	Analyst
7/25/2025	$14.50	Overweight → Equal Weight	Wells Fargo
7/8/2025	$30.00	Buy	Ladenburg Thalmann
12/2/2024	$18.00 → $30.00	In-line → Outperform	Evercore ISI
10/16/2024	$24.00 → $30.00	Neutral → Buy	H.C. Wainwright
11/20/2023	$15.00	Neutral	JP Morgan
8/28/2023	$85.00 → $25.00	Buy → Neutral	H.C. Wainwright
8/8/2023	$45.00	Neutral → Overweight	Piper Sandler
8/4/2023	$51.00	Outperform	SVB Securities

More analyst ratings

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

2/9/24 9:28:31 AM ET

$NVCR

Medical/Dental Instruments

Health Care

Get the next $NVCR alert in real time by email

Recent Analyst Ratings for

$NVCR

Date	Price Target	Rating	Analyst
7/25/2025	$14.50	Overweight → Equal Weight	Wells Fargo
7/8/2025	$30.00	Buy	Ladenburg Thalmann
12/2/2024	$18.00 → $30.00	In-line → Outperform	Evercore ISI
10/16/2024	$24.00 → $30.00	Neutral → Buy	H.C. Wainwright
11/20/2023	$15.00	Neutral	JP Morgan
8/28/2023	$85.00 → $25.00	Buy → Neutral	H.C. Wainwright
8/8/2023	$45.00	Neutral → Overweight	Piper Sandler
8/4/2023	$51.00	Outperform	SVB Securities

More analyst ratings

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NVCR

SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NVCR

$NVCR
Insider Trading

Former Chief Medical Officer Leupin Nicolas sold $14,636 worth of Ordinary Shares (1,100 units at $13.31), decreasing direct ownership by 1% to 102,979 units (SEC Form 4)

Former Chief Executive Officer Cordova Ashley covered exercise/tax liability with 17,638 units of Ordinary Shares, decreasing direct ownership by 4% to 422,570 units (SEC Form 4)

General Counsel Ben Arye Barak was granted 50,125 units of Ordinary Shares, increasing direct ownership by 26% to 242,453 units (SEC Form 4)

$NVCR
Analyst Ratings

NovoCure downgraded by Wells Fargo with a new price target

Ladenburg Thalmann initiated coverage on NovoCure with a new price target

NovoCure upgraded by Evercore ISI with a new price target

$NVCR
Press Releases

Novocure to Report First Quarter 2026 Financial Results

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

$NVCR
Insider Purchases

Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

$NVCR
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by NovoCure Limited

NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by NovoCure Limited

$NVCR
FDA approvals

October 18, 2024 - FDA Roundup: October 18, 2024

$NVCR
Leadership Updates

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

$NVCR
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by NovoCure Limited

Amendment: SEC Form SC 13G/A filed by NovoCure Limited